ipilimumab
Quick Summary
Ipilimumab is a type of drug known as an immune checkpoint inhibitor (ICI). ICIs work by enhancing the immune system's ability to fight cancer cells. They do this by blocking proteins called checkpoints, which normally prevent the immune system from overreacting and harming healthy cells.1
Ipilimumab was the first ICI approved by the U.S. Food and Drug Administration (FDA) in 2011, specifically for treating advanced melanoma. It is a monoclonal antibody that targets and blocks a protein called CTLA-4. CTLA-4 normally acts as a brake on T-cells, which are key immune cells. By blocking CTLA-4, ipilimumab releases this brake, allowing T-cells to more effectively attack cancer cells. This approach has been a significant advancement in cancer treatment.23451
Ask Britannica AI about this topic
Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.
immune systemImmunity against cancerKnown as ipilimumab (Yervoy), the antibody was approved in 2011 by the U.S. Food and Drug Administration for the treatment of late-stage melanoma. Likewise, the discovery of a negative immune regulatory protein known as programmed cell death protein 1 (PD-1), which occurs on the surface of T…
Read MoreKnown as ipilimumab (Yervoy), the antibody was approved in 2011 by the U.S. Food and Drug Administration for the treatment of late-stage melanoma. Likewise, the discovery of a negative immune regulatory protein known as programmed cell death protein 1 (PD-1), which occurs on the surface of T…
Read More
cancerImmunotherapy…approach has been demonstrated with ipilimumab, a monoclonal antibody approved for the treatment of advanced melanoma that binds to and blocks the activity of cytotoxic lymphocyte associated antigen 4 (CTLA4). CTLA4 normally is a powerful inhibitor of T cells. Thus, by releasing the inhibitory signal, ipilimumab augments the immune response,…
Read More…approach has been demonstrated with ipilimumab, a monoclonal antibody approved for the treatment of advanced melanoma that binds to and blocks the activity of cytotoxic lymphocyte associated antigen 4 (CTLA4). CTLA4 normally is a powerful inhibitor of T cells. Thus, by releasing the inhibitory signal, ipilimumab augments the immune response,…
Read More- cancerMilestones in cancer science
Cancer immunotherapies—such as ipilimumab, nivolumab, and pembrolizumab—were also developed. These therapies, though they were associated with potentially dangerous side effects, were especially effective in mobilizing immune cells to fight tumors. American immunologist James P. Allison and Japanese immunologist Tasuku Honjo
Read MoreCancer immunotherapies—such as ipilimumab, nivolumab, and pembrolizumab—were also developed. These therapies, though they were associated with potentially dangerous side effects, were especially effective in mobilizing immune cells to fight tumors. American immunologist James P. Allison and Japanese immunologist Tasuku Honjo
Read More